Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 2 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Precedo Pharmaceuticals Co. Ltd. is currently managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 2 distinct examiners and 2 distinct art units. This distribution shows that while the portfolio is focused on an individual technology area, the workload is split between different points of review. The presence of 5 pending actions suggests an active phase of prosecution for the company's pharmaceutical interests.
The busiest examiner for the portfolio is EBBINGHAUS, BRIANA NOEL, who is responsible for 4 busiest examiner pending office actions. This means that 4 of the pending office actions are concentrated under an individual examiner's review. The remaining workload is handled by the other of the distinct examiners. Practitioners should prioritize understanding the specific examination patterns of EBBINGHAUS, BRIANA NOEL, as the outcomes from this examiner will heavily influence the overall success of the company's current patenting efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EBBINGHAUS, BRIANA NOEL | 4 | 59.7% | +63.0% |
| RAHMAN, MASUDUR | 1 | 72.9% | +31.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577457 | CULTURE MEDIUM FOR LUNG CANCER EPITHELIAL CELLS, CULTURE METHOD, AND APPLICATION THEREOF | EBBINGHAUS, BRIANA NOEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18700796 | CULTURE MEDIUM FOR PRIMARY OVARIAN CANCER CELLS, CULTURE METHOD AND APPLICATION THEREOF | EBBINGHAUS, BRIANA NOEL | — |
| 18692569 | CULTURE MEDIUM AND CULTURE METHOD FOR LUNG CANCER EPITHELIAL CELLS, AND APPLICATION THEREOF | EBBINGHAUS, BRIANA NOEL | — |
| 18690412 | CULTURE MEDIUM FOR HEPATOMA ORGANOID CULTURE, HEPATOMA ORGANOID CULTURE METHOD, AND APPLICATION THEREOF | EBBINGHAUS, BRIANA NOEL | — |
| 18685054 | Culture Medium and Culture Method for Human Primary Acute Myeloid Leukemia Cells | RAHMAN, MASUDUR | — |
| 18577457 | CULTURE MEDIUM FOR LUNG CANCER EPITHELIAL CELLS, CULTURE METHOD, AND APPLICATION THEREOF | EBBINGHAUS, BRIANA NOEL | — |
| Art Unit | Apps |
|---|---|
| 1632 | 4 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700796 | CULTURE MEDIUM FOR PRIMARY OVARIAN CANCER CELLS, CULTURE METHOD AND APPLICATION THEREOF | EBBINGHAUS, BRIANA NOEL | 1632 | §112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18692569 | CULTURE MEDIUM AND CULTURE METHOD FOR LUNG CANCER EPITHELIAL CELLS, AND APPLICATION THEREOF | EBBINGHAUS, BRIANA NOEL | 1632 | §112DP | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18690412 | CULTURE MEDIUM FOR HEPATOMA ORGANOID CULTURE, HEPATOMA ORGANOID CULTURE METHOD, AND APPLICATION THEREOF | EBBINGHAUS, BRIANA NOEL | 1632 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2024 |
| 18685054 | Culture Medium and Culture Method for Human Primary Acute Myeloid Leukemia Cells | RAHMAN, MASUDUR | 1633 | §103 | Final Rejection | — | Pending | Feb 20, 2024 |
| 18577457 | CULTURE MEDIUM FOR LUNG CANCER EPITHELIAL CELLS, CULTURE METHOD, AND APPLICATION THEREOF | EBBINGHAUS, BRIANA NOEL | 1632 | §103§112Other | Non-Final OA | — | Pending | Jan 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPrecedo Pharmaceuticals Co. Ltd. has 5 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Briana Noel Ebbinghaus has the most, with 4 of Precedo Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
